Division of Baxter International Inc.
Latest From Baxter AG
Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma
Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.
Data necessary for regulatory approval may not be sufficient for prescribers, Pfizer’s Sophie Opdyke tells Pharmaceutical Strategy Conference.
Generic user fees could be segmented further by addition of new group.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Baxter International Inc.
- Senior Management
- Contact Info
Phone: (43) 20100 - 0
Wien, A - 1221
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.